The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11033 malaria professionals are enjoying the free benefits of MalariaWorld today

merozoite surface protein 1

Structure of the merozoite surface protein 1 from Plasmodium falciparum

June 9, 2021 - 13:06 -- Open Access
Author(s): 
Dijkman PM, Marzluf T, Zhang Y, Chang SS, Helm D, Lanzer M, Bujard H, Kudryashev M
Reference: 
Sci Adv. 2021 Jun 2;7(23):eabg0465

The merozoite surface protein 1 (MSP-1) is the most abundant protein on the surface of the erythrocyte-invading Plasmodium merozoite, the causative agent of malaria. MSP-1 is essential for merozoite formation, entry into and escape from erythrocytes, and is a promising vaccine candidate. Here, we present monomeric and dimeric structures of full-length MSP-1. MSP-1 adopts an unusual fold with a large central cavity.

Molecular epidemiology of Plasmodium falciparum by multiplexed amplicon deep sequencing in Senegal

November 11, 2020 - 14:30 -- Open Access
Author(s): 
Tolla Ndiaye, Mouhamad Sy, Daouda Ndiaye, et al.
Reference: 
Malaria Journal 2020 19:403, 10 November 2020

Molecular epidemiology can provide important information regarding the genetic diversity and transmission of Plasmodium falciparum, which can assist in designing and monitoring elimination efforts. However, malaria molecular epidemiology including understanding the genetic diversity of the parasite and performing molecular surveillance of transmission has been poorly documented in Senegal. Next Generation Sequencing (NGS) offers a practical, fast and high-throughput approach to understand malaria population genetics. This study aims to unravel the population structure of P. falciparum and to estimate the allelic diversity, multiplicity of infection (MOI), and evolutionary patterns of the malaria parasite using the NGS platform.

Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial

February 11, 2020 - 16:26 -- Open Access
Author(s): 
Antje Blank, Kristin Fürle, Hermann Bujard, et al.
Reference: 
npj Vaccines 5, 10 (2020)

A vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) in combination with GLA-SE adjuvant. Thirty-two healthy volunteers were vaccinated at least three times with MSP1 plus adjuvant, adjuvant alone, or placebo (24:4:4) to evaluate the safety and immunogenicity.

Subscribe to RSS - merozoite surface protein 1